Physician profile
Michael J Pflughoft
NPI 1023080223
$3,743.92
in general payments reported to CMS, 2019-2025
21 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,490 · 2023: $1,989 · 2024: $143 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,113 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,113.40 |
| Education | $140.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $762.09 | 2022-2023 | Austedo Xr, Austedo, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $475.38 | 2022-2023 | |
| Abbvie INC. | $431.76 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $299.89 | 2022-2023 | Spravato |
| Corium, LLC | $280.25 | 2022-2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $275.38 | 2022-2023 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $240.24 | 2022-2023 | Aristada, Lybalvi |
| Nalu Medical, INC. | $142.50 | 2024 | Nalu Neurostimulation System |
| Lundbeck LLC | $129.02 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $123.69 | 2022-2023 | Belsomra |
| Sanofi-Aventis U.S. LLC | $121.83 | 2025 | |
| Indivior INC. | $115.32 | 2022-2023 | Perseris |
| Vanda Pharmaceuticals INC. | $94.96 | 2022-2023 | Hetlioz, Fanapt |
| Sunovion Pharmaceuticals INC. | $79.98 | 2022 | |
| Idorsia Pharmaceuticals US INC | $42.94 | 2022-2023 | Quviviq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $34.63 | 2023 | Jornay Pm |
| Neurocrine Biosciences, INC. | $27.96 | 2022 | |
| Supernus Pharmaceuticals, INC. | $19.12 | 2023 | Qelbree |
| Eisai INC. | $17.18 | 2022 | |
| Axsome Therapeutics, INC. | $15.40 | 2022 | |
| Noven Therapeutics, LLC | $14.40 | 2023 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pflughoft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.